Current Issue ( Vol. : 6, Issue: 3, July-September 2019 2019)   

Title: Author's Guidelines
Author: Editor
Page No: 1-3
Abstract: Manuscript must be typed on A-4 size paper with 2.54 cm. or 1” inch margin all around, with 12 font size (times new roman), single spaced in English and should be submitted via email at [email protected] or through our submission portal following the link manuscript.html together with covering letter from corresponding author as a file saved in Ms-Word (.doc). Before submitting spelling, punctuation, sentence structure and spacing should be properly checked. Download PDF

Author: Om Prakash Agrawal, CK Tyagi, Deenanath Jhade
Keyword: Conora Virus, Chloroquine, Vaccine, Hydroxychloroquine.
Page No: 01-06
DOI: 10.30876/JOHR.7.1.2020.01-06
Abstract: A novel coronavirus disease (COVID-19), triggered by infection with SARS-CoV-2, has flounced across 31 provinces in China and over 195 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is extremely probable to be due to unrestrained cytokine release. There is a crucial need to classify safe and active drugs for action. Chloroquine (CQ) exhibitions an inhibitory effect. However, the clinical use of CQ can cause severe side effects. Moreover, hydroxyl-chloroquine (HCQ) also exhibits an antiviral effect highly similar to that of CQ, inhibiting the cytokine storm by suppressing T-cell activation. Coronavirus vaccine will be carry after clinical trials ahead in markets.Download PDF